胃癌、食管癌中NY-ESO-1抗原特异性免疫应答与生存率的关系研究

陈军; 尚小云; 唐波; 钱锋; 石彦; 余佩武

您当前的位置：

首页 >

文章列表页 >

胃癌、食管癌中NY-ESO-1抗原特异性免疫应答与生存率的关系研究

论著 | 更新时间：2026-01-09

- 胃癌、食管癌中NY-ESO-1抗原特异性免疫应答与生存率的关系研究
- Antigen expression and cellular immunogenicity of NY-ESO-1 in gastric and esophageal cancer
- 陆军军医大学学报 2009年31卷第10期页码：984-986
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：
  中图分类号： {R392.13};R730.23;R735
- 纸质出版：2009
- 稿件说明：
移动端阅览
陈军,尚小云,唐波,钱锋,石彦,余佩武.胃癌、食管癌中NY-ESO-1抗原特异性免疫应答与生存率的关系研究[J].陆军军医大学学报(原第三军医大学学报),2009,31(10):984-986.

　CHEN Jun,SHANG Xiao-yun,TANG Bo,QIAN Feng,SHI Yan,YU Pei-wu.Antigen expression and cellular immunogenicity of NY-ESO-1 in gastric and esophageal cancer[J].J Amry Med Univ (J Third Mil Med Univ),2009,31(10):984-986.
陈军,尚小云,唐波,钱锋,石彦,余佩武.胃癌、食管癌中NY-ESO-1抗原特异性免疫应答与生存率的关系研究[J].陆军军医大学学报(原第三军医大学学报),2009,31(10):984-986. DOI：

　CHEN Jun,SHANG Xiao-yun,TANG Bo,QIAN Feng,SHI Yan,YU Pei-wu.Antigen expression and cellular immunogenicity of NY-ESO-1 in gastric and esophageal cancer[J].J Amry Med Univ (J Third Mil Med Univ),2009,31(10):984-986. DOI：

摘要

目的分析胃癌、食管癌中NY-ESO-1抗原基因的表达分布、NY-ESO-1

157-165

表位引发的特异性细胞免疫应答的状态与生存率的关系。方法利用RT-PCR方法检测112例胃癌和76例食管癌患者肿瘤标本和正常胃黏膜中NY-ESO-1抗原基因的表达，应用多色流式分析结合HLA-A2限制性表位肽/五聚体复合物技术对胃癌、食管癌患者外周血NY-ESO-1

157-165

表位特异性CTL进行精确定量。回顾分析20例NY-ESO-1

/HLA-A2

患者，随访3年，比较不同免疫应答状态对生存率的影响。结果食管癌患者中NY-ESO-1 mRNA表达频率（36.8%）明显高于胃癌（13.4%）。在20例检测到的NY-ESO-1

HLA-A2

患者中，强反应者（CD8

pentamer

cells ≥0.5%）生存率明显高于弱反应者（CD8

pentamer

cells＜0.5%）（P＜0.01）。结论胃癌、食管癌患者均有不同程度表达NY-ESO-1，其特异性免疫应答被检测到，并与生存率有关。

Abstract

Objective To analyze the relationship between the CTL response of NY-ESO-1 in gastric and esophageal cancer and survival rate in Chinese in order to provide data to develop a vaccine against the NY-ESO-1 positive cancer. Methods One hundred and twelve gastric cancer specimens and seventy-six esophageal cancer specimens were analyzed for the expression of NY-ESO-1 mRNA by RT-PCR. Pentamer staining were performed to analyze the frequency of NY-ESO-1

157-165

specific CTL in

NY-ESO-1/HLA-A2 positive patients. The correlation of CTL response and survival rate were analyzed. Results About 13.4% of the gastric cancer and 36.8% of the esophageal cancer were NY-ESO-1 positive. There were 23 patients with NY-ESO-1/HLA-A2 double positive. Frequency of Pentamer staining analysis and survival rate of these NY-ESO-1/HLA-A2 double positive patients indicated that high survival rate correlate with strong cellular immune response. Conclusion NY-ESO-1 expression is found in some of gastric and esophageal cancer

and NY-ESO-1

157-165

peptide can be regarded as a candidate for vaccination due to their expression and CTL response.

关键词

Keywords

references

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

奥沙利铂通过诱导胃癌细胞铜死亡抑制胃癌

LncRNA FGD5-AS1通过调节miR-302b-3p/E2F1轴对胃癌细胞迁移及侵袭的影响

转录因子TGIF1高表达胃癌的免疫抑制性微环境特征及临床意义分析

基于DAEUnet和ConvNeXt网络的食管癌智能分割与分期诊断模型构建

内镜下LCPL征象对胃黏膜高危肠上皮化生的诊断价值